Table S2 The peptidome peptides identified from the pooled breast cancer patients (BCP) and control healthy persons (HP) blood plasma samples. Found at: doi:10.1371/journal.pone.0013133.s002 (0.95 MB DOC) Table S3 The MMPs identified from the pooled breast cancer patients (BCP) and control healthy persons (HP) blood plasma proteomic samples. Found at: doi:10.1371/journal.pone.0013133.s003 (0.06 MB DOC) Figure S1 The HC1-3 composed of protein complexes IaI, PaI and IaIL that function to stabilize the ECM. The red and blue numbers represent the different peptidome peptides observed for the BCP and the control HP, respectively. Found at: doi:10.1371/journal.pone.0013133.s004 (0.06 MB DOC) Figure S2 The selective degradation of the BCP complement system convertases and MAC components would lead to the system dysfunction. The key convertases C3b, C4b, and factor B and MAC components C8 and C9 in the complement system that limits tumor growth are differentially degraded on their function domains for the BCP; the grey arrows represent the activation routes to be limited due to the excessive degradation [1]. The red and blue numbers represent the different peptides observed for the BCP and the control HP, respectively. 1 Markiewski MM, Lambris JD (2009) Is complement good or bad for cancer References 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249. 2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752. 3. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Bru¨ nner N, et al. (2008) National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54: e11–e79. 4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287–5312. 5. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845–867. 6. Koblinski JE, Ahram M, Sloane BF (2000) Unraveling the role of proteases in cancer. Clin. Chim Acta 291: 113–135. 7. Puente XS, Sa´nchez LM, Overall CM, Lo´pez-Ot´ın C (2003) Human and mouse proteases: a comparative genomic approach. Nature Rev Genet 4: 544–558. 8. Lo´pez´ın-Ot´ın C, Overall CM (2002) Proteases degradomics: a new challenge for proteomics. Nature Rev Mol Cell Biol 3: 509–519. 9. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964. 10. Petricoin EF, Belluco C, Araujo RP, Liotta LA (2006) The blood peptidome: another dimension of information content for cancer biomarker discovery. Nature Rev Cancer 6: 961–967. 11. Liotta LA, Ferrari M, Petricoin E (2003) Clinical proteomics: written in blood. Nature 425: 905–905. 12. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, et al. (2006) Differential exoprotease activities confer tumor-specific peptidome patterns. J Clin Invest 116: 271–284. 13. Shen Y, Liu T, Tolic´ N, Petritis BO, Zhao R, et al. (2010) Strategy for degradomic-peptidomic analysis of human blood plasma. J Proteome Res 9: 2339–2346. 14. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, et al. (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139–266. 15. Petersen TE, Martzen MR, Ichinose A, Davie EW (1990) Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 265: 6104–6111. 16. Potempa J, Shieh B-H, Travis J (1988) Alpha-2-antiplasmin: a serpin with two separate but overlapping reactive sites. Science 241: 699–241. 17. Albini A, Sporn MB (2007) The tumor microenvironment as a target for chemoprevention. Nature Rev Cancer 7: 139–147. 18. Shvyrkova IG, Muranova TA (2000) Proteolytic specificity of plasmin toward adhesive proteins. Russ J Bioorg Chem 26: 317–321. Breast Cancer Degradomic View Data S1 Found XLSX) Acknowledgments patients? A new perspective on an old dilemma. Trends Immun 30: 286–292. Found at: doi:10.1371/journal.pone.0013133.s005 (0.23 MB DOC) Figure S3 The BCP and the control HP peptidome peptide molecular weight distributions. The BCP and HP peptidomes were isolated with use of size exclusion chromatography. Found at: doi:10.1371/journal.pone.0013133.s006 (0.08 MB DOC) at: doi:10.1371/journal.pone.0013133.s007 (1.36 MB Work was performed in the Environmental Molecular Science Laboratory, a DOE/BER national scientific user facility located on the campus of Pacific Northwest National Laboratory (PNNL) in Richland, Washington. PNNL is a multi-program national laboratory operated by Battelle Memorial Institute for the DOE under contract DE-AC05-76RLO-1830. Author Contributions Conceived and designed the experiments: YS DGC. Performed the experiments: YS TL RZ BP MG RJM. Analyzed the data: YS NT SOP. Contributed reagents/materials/analysis tools: YS. Wrote the paper: YS NT TL DGC FE RDS. Provided breast cancer samples: FE. 19. Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22. 20. Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124: 58S–68S. 21. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, et al. (1993) Thrombin increases the metastatic potential of tumor cells. Int J Cancer 54: 793–806. 22. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387–2392. 23. Weigelt B, Peterse JL, van ’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nature Rev Cancer 5: 591–602. 24. Liotta LA, Kohn EC (2001) The microenvironment of the tumor-host interface. Nature 411: 375–379. 25. Sanggaard KW, Sonne-Schmidt CS, Krogager TP, Lorentzen KA, Wisniewski HG, et al. (2008) The transfer of heavy chains from bikunin proteins to hyaluronan requires both TSG-6 and HC2. J Biol Chem 283: 18530–18537. 26. Bost F, Diarra-Mehrpour M, Martin JP (1998) Inter-alpha-trypsin inhibitor proteoglycan family-a group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem 252: 339–346. 27. He H, Li W, Tseng DY, Zhang S, Chen SY, et al. (2009) Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HC*HA) purified from extracts of human amniotic membrane. J Biol Chem 284: 20136–20146. 28. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344: 1058–1066. 29. Markiewski MM, Lambris JD (2009) Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immun 30: 286–292. 30. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P (2006) Structure of C3b reveals conformational changes that underlie complementary activity. Nature 444: 213–216. 31. Janssen BJ, Huizinga EG, Raaijmakers HC, Roos A, Daha MR, et al. (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437: 505–511. 32. Niculescu F, Rus HG, Retegan M, Vlaicu R (1992) Persistent complement activation on tumor cells in breast cancer. Am J Pathol 140: 1039–1043. 33. Schapira DV, Schapira M (1983) Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer. Breast Cancer Res Treat 3: 221–224. 34. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, et al. (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285: 245–248. PLoS ONE | www.plosone.org 12 October 2010 | Volume 5 | Issue 10 | e13133